%0 Journal Article
%T New-onset type 2 DM risk in dyslipidemia and stroke patients due to simvastatin use
%A Ema Pristi Yunita
%A Widya Pratiwi Suryanti
%A Didi Candradikusuma
%J Journal of Advanced Pharmacy Education and Research
%@ 2249-3379
%D 2021
%V 11
%N 3
%R 10.51847/qvunlqV9fN
%P 137-143
%X Simvastatin is a therapy management for dyslipidemia and stroke, which are prevalent in Indonesia. These drugs are very effective in reducing the incidence of cardiovascular disease and mortality in high-risk patients. However, long-term use of simvastatin may lead to new problems, such as the risk of new-onset type 2 DM. This study aims to monitor the blood glucose profile to determine the risk of new-onset type 2 DM. This study is observational with a prospective one-group pre-test and post-test design conducted at the outpatient polyclinic of UNISMA Islamic Hospital Malang from February to June 2018. The sample consisted of patients who received a long-term simvastatin therapy dose of 20 mg. A paired t-test was performed when the data were normally distributed to determine the significance of FPG and HbA1c levels changes. The results showed that the increase in fasting plasma glucose (FPG) levels at the first and third months was not statistically significant (97.44 mg/dL vs. 100.33 mg/dL; p = 0.196). Similarly, the increase in HbA1c levels was not statistically significant (6.79% vs. 7.53%; p = 0.076). However, the results of FPG and HbA1c showed that all patients (27 people) have the possibility of experiencing new-onset type 2 DM. In short, routine intake of 20 mg simvastatin with a minimum usage duration of 6 months has caused 27 patients to experience a new-onset type 2 DM‎.
%U https://japer.in/article/new-onset-type-2-dm-risk-in-dyslipidemia-and-stroke-patients-due-to-simvastatin-use-bnvyakpxsrhxrpq